|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
IL99552A0
(en)
|
1990-09-28 |
1992-08-18 |
Ixsys Inc |
Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
|
|
WO1993015766A1
(en)
|
1992-02-10 |
1993-08-19 |
Seragen, Inc. |
Desensitization to specific allergens
|
|
GB9305735D0
(en)
|
1993-03-19 |
1993-05-05 |
North John R |
Novel agent for controlling cell activity
|
|
GB9508204D0
(en)
|
1995-04-21 |
1995-06-07 |
Speywood Lab Ltd |
A novel agent able to modify peripheral afferent function
|
|
GB9617671D0
(en)
|
1996-08-23 |
1996-10-02 |
Microbiological Res Authority |
Recombinant toxin fragments
|
|
US7192596B2
(en)
|
1996-08-23 |
2007-03-20 |
The Health Protection Agency Ipsen Limited |
Recombinant toxin fragments
|
|
GB9721189D0
(en)
|
1997-10-08 |
1997-12-03 |
Speywood Lab The Limited |
Analgesic conjugates
|
|
CN1241945C
(zh)
|
1998-05-13 |
2006-02-15 |
拜欧特康生化技术开发和咨询有限公司 |
用于抑制肥大细胞脱粒的杂合蛋白质及其用途
|
|
DE69910216T2
(de)
|
1998-07-22 |
2004-02-19 |
Osprey Pharmaceuticals Ltd., Calgary |
Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
|
|
GB9818548D0
(en)
|
1998-08-25 |
1998-10-21 |
Microbiological Res Authority |
Treatment of mucas hypersecretion
|
|
US6776990B2
(en)
|
1999-04-08 |
2004-08-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pancreatitis
|
|
US6358697B2
(en)
|
1999-04-21 |
2002-03-19 |
Children's Hospital Medical Center |
Intracellular pharmaceutical targeting
|
|
ATE348178T1
(de)
|
1999-08-25 |
2007-01-15 |
Allergan Inc |
Aktivierbare rekombinante neurotoxine
|
|
GB9922554D0
(en)
|
1999-09-23 |
1999-11-24 |
Microbiological Res Authority |
Inhibition of secretion from non-neuronal cells
|
|
US7172764B2
(en)
*
|
2003-11-17 |
2007-02-06 |
Allergan, Inc. |
Rescue agents for treating botulinum toxin intoxications
|
|
DE102004043009A1
(de)
|
2004-09-06 |
2006-03-23 |
Toxogen Gmbh |
Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
|
|
AU2005311086B2
(en)
|
2004-12-01 |
2012-03-29 |
Allergan, Inc. |
Fusion proteins
|
|
DE102005019302A1
(de)
|
2005-04-26 |
2006-11-16 |
Toxogen Gmbh |
Carrier zum Targeting von Nervenzellen
|
|
ATE518882T1
(de)
|
2005-09-19 |
2011-08-15 |
Allergan Inc |
Mit clostridientoxin aktivierbare clostridientoxine
|
|
AU2007272515B2
(en)
|
2006-07-11 |
2013-09-26 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
|
|
WO2008008805A2
(en)
|
2006-07-11 |
2008-01-17 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
|
|
UA116985C2
(uk)
|
2012-05-30 |
2018-06-11 |
Президент Енд Феллоуз Оф Гарвард Колледж |
Рекомбінантний ботулінічний нейротоксин
|
|
GB201312317D0
(en)
|
2013-07-09 |
2013-08-21 |
Syntaxin Ltd |
Cationic neurotoxins
|
|
WO2016110662A1
(en)
|
2015-01-09 |
2016-07-14 |
Ipsen Bioinnovation Limited |
Cationic neurotoxins
|
|
PT3274364T
(pt)
|
2015-03-26 |
2021-11-05 |
Harvard College |
Neurotoxina botulínica manipulada
|
|
GB201607901D0
(en)
|
2016-05-05 |
2016-06-22 |
Ipsen Biopharm Ltd |
Chimeric neurotoxins
|
|
EP3481852B1
(en)
*
|
2016-07-08 |
2022-12-07 |
Children's Medical Center Corporation |
A novel botulinum neurotoxin and its derivatives
|
|
TWI822723B
(zh)
|
2018-01-29 |
2023-11-21 |
英商艾普森生物製藥有限公司 |
非神經元性 SNARE 裂解的肉毒桿菌神經毒素、裂解 hSNAP-23 之活體外方法、及經修飾 BoNT/A L 鏈蛋白酶之用途
|
|
GB201815817D0
(en)
|
2018-09-28 |
2018-11-14 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising and exogenous activation loop
|
|
US20220220466A1
(en)
*
|
2019-04-17 |
2022-07-14 |
Children's Medical Center Corporation |
Catalytically inactive botulinum neurotoxin-like toxins and uses thereof
|
|
GB201914034D0
(en)
*
|
2019-09-30 |
2019-11-13 |
Ipsen Biopharm Ltd |
Treatment of neurological disorders
|